Tryptophan is mainly metabolized in the brain through methoxyindole and kynurenine pathways. The methoxyindole pathway produces (among other compounds) melatonin, which displays inhibitory effects on human and animal central nervous systems, including a significant attenuation of excitatory, glutamate-mediated responses. The kynurenine pathway produces kynurenines that interact with brain glutamate-mediated responses. Nitric oxide (NO) increases glutamate release, and melatonin and kynurenines may act via modification of NO synthesis. In the present study, the effects of melatonin and four synthetic kynurenines were studied on the activity of rat striatal nitric oxide synthase (NOS) and on the response of rat striatal neurons to sensorimotor cortex (SMCx) stimulation, a glutamate-mediated response. Melatonin inhibited both NOS activity and the striatal glutamate response, and these effects were dose-related. Compound A (2-acetamide-4-(3-methoxyphenyl)-4-oxobutyric acid) did not inhibit NOS activity but inhibited the striatal response similarly to melatonin. Compound B (2-acetamide-4-(2-amino-5-methoxyphenyl)-4-oxobutyric acid) was more potent than melatonin in inhibiting both NOS activity and the striatal response. Compound C (2-butyramide-4-(3-methoxyphenyl)-4-oxobutyric acid) did not change NOS activity, but increased the striatal response. Compound D (2-butyramide-4-(2-amino-5-methoxyphenyl)-4-oxobutyric acid) showed potent inhibitory effects on both NOS activity and striatal glutamate-mediated response. A structure-related effect of the kynurenine derivatives was observed, and those with an amino group in position 2 of the benzenic ring had more potent effects than melatonin itself in inhibiting striatal NOS activity and the response of striatal neurons to SMCx.
Altered glutamatergic neurotransmission and postsynaptic
Inhibitory actions of melatonin in the rat (5, 6) and human (7) central nervous system (CNS) have been reported. These neuronal dysfunctions seem crucial to the etiology of several neurological alterations such as Parkinson's, Alzheimer's and inhibitory actions may be the cause of the anticonvulsant (8, 9), sedative (10) and hypnotic properties of melatonin epilepsy (1, 2) . Acute brain insults (hypoxia and/or ischemia) also trigger glutamate release. Glutamate, acting on ionoreported in humans and several animals (11, 12). In humans and experimental animals, melatonin has antiepileptic and tropic receptors [mainly N-methyl--aspartate (NMDA)], increases Ca2+ influx into cells, resulting in the formation of antiparkinsonian properties (13, 14) and was reported to counteract seizures in nontreatable infantile epilepsy (15). In nitric oxide (NO) by nitric oxide synthase (NOS ) through a calcium-calmodulin dependent mechanism (3). NO diffuses human temporal slices, low-magnesium epileptiform activity is counteracted by melatonin, suggesting an action on NMDA out and further increases glutamate release, acting as a retrograde messenger (4) . While NO is necessary in physioreceptors (7). Other experiments have also suggested an inhibitory role of melatonin on glutamate receptors and, logical conditions, its production must be closely regulated to avoid excessive glutamate release. Thus, a significant in particular, melatonin attenuates glutamate-mediated responses in the rat striatum (16). The inhibitory effects of increase in brain NOS activity and NO production may be related to excitotoxicity. melatonin in the striatum may be mediated through inhibition of NOS, as has been reported in rat cerebellum and hypothalof melatonin. Molecules lacking the NH 2 group in R 1 position (compounds A and C ) did not affect NOS activity at concenamus (17) (18) (19) . This effect, and the free radical scavenging role of the indoleamine (20), may be related to the neuroprotrations of up to 1 mM. The amino group in R 1 position (compounds B and D) conferred upon these molecules tective action of melatonin (6, (21) (22) (23) .
Melatonin is a product of the metabolism of tryptophan, 100-fold more activity than that possessed by melatonin itself, and doses of 10 pM of compounds B or D are enough to the source of several compounds that act on the NMDA receptor. Whereas melatonin is a metabolite of the methoxyinreduce NOS activity significantly. At maximal concentrations tested (1 mM ), compound B was the most potent of the dole pathway of tryptophan metabolism, the kynurenine pathway, which is the other main metabolic route of tryptostructures tested to inhibit NOS activity, whereas the inhibition produced by compound D was similar to that of melaphan in the brain, produces a series of kynurenines that interact with the NMDA receptor complex with agonist and tonin. NOS activity was completely inhibited in the presence of ethylen-glycol-bis-(b-aminoethyl eter)-tetraacetic acid antagonist properties (24, 25) . In addition, the major natural metabolites of melatonin are kynurenines (26) .
(EGTA) (data not shown).
Melatonin significantly reduced NOS activity by 20.8% at Because of the potential neuroprotective role of melatonin, we are currently searching for compounds structurally related dose of 1 nM, reaching a 60.3% reduction at 1 mM concentration (Fig. 1 ). The effect of melatonin at 1 mM was significto melatonin, but with more potent inhibitory effects on the brain. The purpose of the present study was to investigate antly different from those reached with lower doses. Compounds A and C did not affect NOS activity at concentrathe effects of melatonin and four synthetic kynurenine derivatives on rat striatal NOS activity, and to compare these effects tions ranged from 10 pM to 1 mM (Fig. 1) . However, compounds B and D at doses of 10 pM significantly reduced with those produced on the striatal response to sensorimotor cortex (SMCx) stimulation, a well known glutamate-mediated NOS activity by 24.2 and 21.4%, respectively (Fig. 1 ). At doses of 1 mM, NOS activity was reduced by compounds B response.
and D by 68.5% and 45%, respectively. These data suggest that compound B is more potent than compound D in Results inhibiting NOS activity. The effects of compounds B and D at doses of 1 mM were significantly different from those Table 1 shows the structure of the four kynurenine derivatives tested. These compounds comprise two groups, in that comobserved with lower doses (Fig. 1 ).
The effects of melatonin and the four kynurenine derivatpounds B and D are the same as A and C, respectively, except that an NH 2 group is present in position 2 of the ives on the excitatory response of striatal neurons to SMCx stimulation were studied in 23 rats. Electrical stimulation was benzenic ring (R 1 , Table 1 ). The effects of melatonin and compounds A, B, C and D on the striatal NOS activity were applied continuously to the deep layers of SMCx and recordstudied in 30 rats (Table 2 ). Low concentrations of melatonin ings were made from a total of 62 neurons in the medial and (1 nM ) produced a significant inhibition of striatal NOS dorsal portion of the striatum. Most of the neurons in this activity, whereas maximal inhibition was reached with 1 mM region were quiescent unless excited by cortical stimulation. They were selected to meet the following criteria (1): they showed an excitatory response to SMCx stimulation, and (2) T 1. Structure of the Kynurenine Derivatives.
the response comprised at least 20 spikes during control recordings (2 min, 60 electrical stimuli, no microiontophoresis). The latency of the excitatory response was relatively short (5-14 ms). The latency of activation of a given neuron
showed little fluctuation and usually appeared in the poststimulus time histogram as a narrow peak (Fig. 2) .
Microiontophoresis of melatonin inhibited the evoked
response in 89.4% of neurons tested (n=62). The maximum
inhibition was observed in the second period (2-4 min after latency of the attenuation was shorter than melatonin (0-2 min). Interestingly, the presence of the NH 2 group in the R 1 position of compound C (yielding compound D) not percentage of neurons (86.7%; n=15) and showed the same latency as melatonin. By contrast, compound C significantly only blunted its facilitatory effects on the excitatory response of striatal neurons to SMCx stimulation, but also attenuated increased the excitatory response in 84.2% of striatal neurons to SMCx stimulation (n=19). In this case, the latency of the 98.8% (n=13) of the striatal excitatory response, with short latency (0-2 min). increase was very short (first period, 0-2 min after starting iontophoresis). In cells previously inhibited by melatonin, simultaneous ejection of melatonin plus compound C proDiscussion duced an increase in the response in 100% of the neurons. When an NH 2 group was present in the R 1 position of The present results show that nanomolar concentrations of melatonin can inhibit NOS activity in the striatum, supporting compound A (yielding compound B), a significant attenuation of the excitatory response of striatal neurons to SMCx previous data showing similar effects in the cerebellum and hypothalamus (17) (18) (19) (20) . Melatonin concentration in the nanoinhibition of NMDA receptors by endogenous NO (37) . It has been suggested that resting neuronal production of NO molar range is present in the rodent and human sera at night (27) and enters the CNS (28); therefore, indoleamine may controls short-term NMDA resting function, whereas prolonged glutamate receptor stimulation yields high local NO participate in the physiological regulation of brain NOS activity. The major natural metabolites of melatonin are concentrations, which may be responsible for delayed glutamate toxicity. Our results show a relationship between inhibikynurenines (26) , and the present results show that synthetic kynurenines also influence NOS activity in a structure-related tion of NOS activity and inhibition of glutamate receptors in melatonin and amino-kynurenines experiments. These inhibitmanner. These data may reflect the regulation of glutamate receptor activity, because NO controls glutamate release. To ory effects of melatonin may be related to the neuroprotective action of melatonin (6, (21) (22) (23) . However, the lack of effect assess this possibility, we studied the effects of melatonin and kynurenine derivatives upon the excitatory response of the of compounds A and C on NOS activity, and their different behaviour in glutamate-mediated responses, suggests more striatal neurons to SMCx stimulation, a glutamate-mediated response (4) . We have previously shown that microiontophorcomplex interactions between the compounds studied here, NOS activity and glutamate receptors. esis of melatonin on striatal neurons produced a dose-related attenuation of this response (16, 29, 30 ). The present data
In conclusion, synthetic kynurenine derivatives with an amino group in position 2 of the benzenic ring have potent confirm this inhibitory effect of melatonin, and show that new, synthetic kynurenines also influence the striatal response effects in inhibiting NOS activity and striatal response to SMCx, although as these results show, kynurenines and in a structure-related fashion. However, whereas melatonin inhibits both striatal NOS activity and the electrophysiolomelatonin may act in different ways. The reason for this dissociation of effects may be that melatonin has receptorgical response, the four kynurenines studied act in a different manner. Kynurenine derivatives with an NH 2 radical in R 1 dependent and receptor-independent actions (6, 20) . However, the potent effects of melatonin and kynurenines in position (compounds B and D) were more potent than melatonin in inhibiting both NOS activity and the striatal inhibiting striatal and NOS activity suggest a possible clinical use of these compounds. response to SMCx. Compounds lacking NH 2 (A and C ) had no effect on NOS activity. However, whereas compound A inhibited striatal excitatory response to SMCx stimulation Materials and methods similarly to melatonin, compound C appeared to act as a functional melatonin antagonist, and significantly enhanced -arginine, -citruline, n-∞(2-hydroxymethyl )piperazine-∞-(2-hydroxypropanesulphonic acid ) ( HEPES), -ditriothreitol (DTT ), leupeptin, the response of the striatum, alone or in the presence of aprotinin, pepstatin, phenilmethylsulphonylfluoride (PMSF ), hypoxantineinhibitory concentrations of melatonin. excitability (33) .
Male Wistar rats (200-250 g) were housed under a 12512 h light5dark cycle with free access to food and water. Rats were sacrificed by cervical Melatonin, and some of the kynurenine derivatives studied dislocation, and striata were quickly collected and immediately used to here, modifies striatal NOS activity, a constitutive type I, measure NOS activity. Upon removal, tissues were cooled in ice-cold homo-NOS isoenzyme. Striatal NOS activity is Ca2+-dependent genizing buffer (25 mM Tris, 0.5 mM DTT, 10 mg/ml leupeptin, 10 mg/ml and is completely inhibited in the presence of EGTA (data pepstatine, 10 mg/ml aprotinine, 1 mM PMSF, pH 7.6). Two striata were not shown). Inhibition of NOS produces both a decrease of placed in 1.25 ml of the same buffer and homogenized in a Polytron (10 s×6). The crude homogenate was centrifuged for 5 min at 1000 g, and aliquots of NO production and an inhibition of glutamate release (34). 
